Company news

Clarity Pharmaceuticals Ltd. news in 2024

Clarity Pharmaceuticals Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Novel FAP-targeted radiopharmaceutical

December 17, 2024

S&P DJI Announces December 2024 Quarterly Rebalance

December 6, 2024

Last patient assessment completed for SARTATE trial

November 27, 2024

First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA

November 25, 2024

Chairperson Address AGM

November 19, 2024

Head-to-head IIT with SAR-bisPSMA

November 17, 2024

Clarity and Nucleus RadioPharma sign MSA

November 10, 2024

Copper-67 SAR-bisPSMA updates

October 15, 2024

Positive guidance from the US FDA on Phase III trial

October 13, 2024

Michelle Parker Promoted to CEO

October 13, 2024

Shareholder briefing - presentation

September 18, 2024

SECuRE trial advances

September 11, 2024

S&P DJI Announces September 2024 Quarterly Rebalance

September 6, 2024

FDA Fast Track Designation 64CU-SAR-bisPSMA

August 22, 2024

Supply agreement for Ac-225 with TerraPower Isotopes

July 15, 2024

Clarity strengthens Cu-64 network with new supply agreement

May 29, 2024

Complete response with Cu-67 SAR-bisPSMA

April 29, 2024

Successful Completion of Retail Entitlement Offer

April 24, 2024

Despatch of Retail Entitlement Offer Booklet

April 3, 2024

Completion of Placement and Institutional Entitlement Offer

March 27, 2024

Investor Presentation

March 25, 2024

Clarity launches $121 million equity raise

March 25, 2024

Trading Halt

March 24, 2024

First participant treated in the last dose escalation cohort

March 21, 2024

Theranostic prostate cancer trial advances to multi-dose

March 15, 2024

Additional COBRA trial data results

March 5, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Initial COBRA results

February 14, 2024

Decks in 2024